We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
4
Jun 2026
Eight companies have been selected to participate in the American Heart Association Heart and Brain Health Accelerator, a specialty track within the 2026 MedTech Innovator (MTI) Accelerator.
4
Jun 2026
A pioneering clinical trial has successfully enabled three patients with end-stage kidney disease to receive previously improbable kidney transplants.
4
Jun 2026
Researchers at Kyushu University have developed a simple, rapid, and low-radiation X-ray technique that can evaluate the severity of a heart condition known as pulmonary valve regurgitation-a common and clinically significant complication after surgical repair of a congenital heart defect known as Tetralogy of Fallot.
4
Jun 2026
Researchers at the Terasaki Institute for Biomedical Innovation and the University of Arizona College of Medicine have developed a topical gel formulation with 4-aminopyridine (4-AP), to treat burn wounds, achieving near-complete closure in 21 days.